Beckman Coulter introduces Sentinel Pancreatic Amylase reagent and calibrator on AU Clinical Chemistry Analyzers

Size: px
Start display at page:

Download "Beckman Coulter introduces Sentinel Pancreatic Amylase reagent and calibrator on AU Clinical Chemistry Analyzers"

Transcription

1 PREVIOUSLY RELEASED BREA, CALIF. (June 23, 2016) Beckman Coulter Diagnostics is pleased to announce the release of a new pancreas specific amylase assay. The Sentinel Pancreatic Amylase reagent and calibrator recently received 510(k) clearance from the U.S. Food and Drug Administration (FDA). The liquid, ready-to-use reagent, distributed by Beckman Coulter and manufactured by Sentinel Diagnostics, is an important expansion to Beckman Coulter s broad menu offering and is available for use on its AU clinical chemistry analyzers, AU480, AU680 and AU5800. The availability of the pancreatic amylase assay allows Beckman Coulter Diagnostics to provide laboratories with the tools needed to confidently diagnose and monitor acute pancreatitis and acute attacks during chronic pancreatitis, said John Blackwood, senior vice president, chemistry and immunoassay business unit, Beckman Coulter Diagnostics.

2 Page 2 of 4 Pancreatic amylase is an enzyme produced by the exocrine tissue of the pancreas and aids in the digestion of starches. The Pancreatic Amylase assay is an in vitro diagnostic test used for the quantitative determination of the pancreatic amylase in serum and plasma by enzymatic colorimetric method. The availability of this assay expands Beckman Coulter s comprehensive menu for the AU family of clinical chemistry analyzers. While amylase is a standard test for the diagnosis of pancreatitis, we remember that there are two primary sources of amylase in the human body: the pancreas and salivary glands. The pancreatic amylase test is specific to pancreas as the tissue of origin, and therefore, provides a more targeted test for the diagnosis of pancreatitis, said Jack Zakowski, Ph.D., FACB, director, scientific affairs and professional relations, Beckman Coulter Diagnostics. The new pancreatic amylase assay offers laboratories: Ease of use with barcoded, ready-to-use liquid reagents Good precision and low-end sensitivity (LOD = 0.5 U/L) Reliable and accurate results within a broad assay range of 4.7-2,000 U/L 30-day reagent onboard stability and 14-day calibration frequency

3 Page 3 of 4 The partnership with Beckman Coulter allows us to reach and assist more laboratories globally to meet their diagnostic needs, said Dr. Ugo De Luca, CEO, Sentinel Diagnostics. We look forward to providing laboratories with specialized options and moving healthcare forward. About Sentinel Diagnostics Sentinel Diagnostics is an Italian company with a long and well established background in the development and production of innovative diagnostic test kits for Clinical Chemistry, Colon Cancer Screening and Molecular Biology to be used on the most complex automated analyzers. Since 1983, Sentinel has privileged the values of quality through technology and innovation and in over thirty years of activity the company has managed to affirm its worldwide market presence. Find out more about Sentinel on About Beckman Coulter Beckman Coulter Diagnostics develops clinical diagnostic products that help advance and optimize the clinical laboratory. Beckman Coulter's instruments, systems and tests help streamline processes to enhance efficiency, reduce costs and speed the delivery of results.

4 Page 4 of 4 For 80 years, Beckman Coulter has been a global leader devoted to providing solutions to laboratories of all sizes, offering a broad portfolio of chemistry, immunoassay, hematology, urinalysis, microbiology, automation and information systems. Beckman Coulter is dedicated to advancing healthcare for every person and moving science, innovation and the lab forward. For more information, visit ###

5

Siemens Healthcare Diagnostics

Siemens Healthcare Diagnostics Siemens Healthcare Diagnostics A Global Industry Leader 3.7bn in sales More than 14,500 employees Serving 30,000 customers in more than 120 countries Approximately 244,000 instruments installed R&D spending

More information

USING THE ACCESS AMH ASSAY IN YOUR LABORATORY

USING THE ACCESS AMH ASSAY IN YOUR LABORATORY INFORMATION BULLETIN USING THE ACCESS AMH ASSAY IN YOUR LABORATORY ///////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////////

More information

Disruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017

Disruptive innovation in molecular diagnostics. Hilde Windels CEO Biocartis 25 March 2017 Disruptive innovation in molecular diagnostics Hilde Windels CEO Biocartis 25 March 2017 1 One of the key innovations in healthcare in the last decade PERSONALISED MEDICINE or HIGH PRECISION MEDICINE From

More information

VISTOGARD will be marketed, sold, and distributed in the US by Wellstat s commercialization

VISTOGARD will be marketed, sold, and distributed in the US by Wellstat s commercialization Contact: Torch Communications Jeremiah Hall, 415-349-5016 jeremiah@torchcommunications.com Wellstat Announces FDA Approval of VISTOGARD (Uridine Triacetate), the First Antidote to Treat Overdoses and Early-Onset

More information

DIRECT ENZYMATIC HbA1c ASSAY

DIRECT ENZYMATIC HbA1c ASSAY DIRECT ENZYMATIC HbA1c ASSAY ACCURATE AND SIMPLE DIAZYME INNOVATIONS IN CLINICAL DIAGNOSTICS About Diazyme Diazyme Laboratories is a Division of General Atomics located in Poway, California. Diazyme uses

More information

Cardiac Assessment Controls

Cardiac Assessment Controls Bio-Rad Laboratories CARDIAC ASSESSMENT CONTROLS Cardiac Assessment Controls Value Assigned for Clinical Laboratory and Point of Care Test Systems Solving the Challenges of Troponin I Testing for the Central

More information

MedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy

MedSurg: Endoscopy Presentation for the Investment Community at DDW. Art Butcher Senior Vice President and President, Endoscopy MedSurg: Endoscopy Presentation for the Investment Community at DDW Art Butcher Senior Vice President and President, Endoscopy Safe Harbor for Forward-Looking Statements This presentation contains forward-looking

More information

Urine/CSF Albumin Reagent. Urine/CSF Albumin Calibrator

Urine/CSF Albumin Reagent. Urine/CSF Albumin Calibrator December 2014 PRODUCT ANNOUNCEMENT AU Clinical Chemistry Systems AU400/400 e, AU480, AU640/640 e, AU680, AU2700, AU5400, and AU5800 Product Urine/CSF Albumin Reagent Urine/CSF Albumin Reagent Urine/CSF

More information

The superior solution for disease state diagnosis. IMMAGE 800 Special Chemistry System

The superior solution for disease state diagnosis. IMMAGE 800 Special Chemistry System The superior solution for disease state diagnosis. IMMAGE 800 Special Chemistry System Blood Banking Centrifugation Chemistry Flow Cytometry Hematology Hemostasis Immunoassay Information Systems Lab Automation

More information

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM

PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM HEMATOLOGY ONCOLOGY PPD S EXPERT HEMATOLOGY AND ONCOLOGY TEAM COMMITTED TO ADVANCING DRUG DEVELOPMENT IN ONCOLOGY $ MARKETPLACE COMPLEXITIES increasingly competitive marketplace and rising cost pressures

More information

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer

Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies selectively targeting genetic drivers of cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer and Loxo Oncology to develop and commercialize two novel oncology therapies

More information

Bio-Rad Laboratories. Cardiac Assessment Controls. Value Assigned for Clinical Laboratory and Point of Care Test Systems

Bio-Rad Laboratories. Cardiac Assessment Controls. Value Assigned for Clinical Laboratory and Point of Care Test Systems Bio-Rad Laboratories Cardiac Assessment Controls Cardiac Assessment Controls Value Assigned for Clinical Laboratory and Point of Care Test Systems Solving the Challenges of Troponin I Testing for the Central

More information

Clinical Chemistry Reagents Brochure

Clinical Chemistry Reagents Brochure Clinical Chemistry Reagents Brochure ekfdiagnostics.com Central Laboratory STANBIOChemistry from EKF Diagnostics Welcome to our Reagents Brochure EKF Diagnostics Stanbio Chemistry menu includes liquid-stable

More information

Universal Biosensors, Inc.

Universal Biosensors, Inc. Universal Biosensors, Inc. ARBN 121 559 993 Buchan Three Tickers Presentation 18 th September 2013 1 Important Disclaimer This presentation is intended to provide a general outline only and is not intended

More information

Clinical Chemisty Reagents Brochure. ekfdiagnostics.com STANBIOChemistry from EKF Diagnostics. Central Laboratory

Clinical Chemisty Reagents Brochure. ekfdiagnostics.com STANBIOChemistry from EKF Diagnostics. Central Laboratory Clinical Chemisty Reagents Brochure ekfdiagnostics.com STANBIOChemistry from EKF Diagnostics Central Laboratory Welcome to our Reagents Brochure EKF Diagnostics Stanbio Chemistry menu includes liquid-stable

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Phase 3 Top-Line Results Show IBRANCE in Combination with Fulvestrant Meets Progression-Free Survival (PFS) Primary Endpoint

Phase 3 Top-Line Results Show IBRANCE in Combination with Fulvestrant Meets Progression-Free Survival (PFS) Primary Endpoint For immediate release: April 15, 2015 Media Contact: Sally Beatty (212) 733-6566 Investor Contact: Ryan Crowe (212) 733-8160 Pfizer Announces PALOMA-3 Trial for IBRANCE (Palbociclib) Stopped Early Due

More information

Introducing A New Platform In Cancer Care Robotically Assisted Sonic Therapy (RAST)

Introducing A New Platform In Cancer Care Robotically Assisted Sonic Therapy (RAST) Introducing A New Platform In Cancer Care Robotically Assisted Sonic Therapy (RAST) CED Life Science Conference February 27, 2018 Almost 40% of us will be diagnosed with cancer at some point in our lives

More information

Background Information

Background Information Background Information Erlangen, November 26, 2017 RSNA 2017 in Chicago: South Building, Hall A, Booth 1937 Artificial intelligence: Transforming data into knowledge for better care Inspired by neural

More information

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650)

NEWS RELEASE Media Contact: Krysta Pellegrino (650) Investor Contact: Sue Morris (650) Advocacy Contact: Kristin Reed (650) NEWS RELEASE Media Contact: Krysta Pellegrino (650) 225-8226 Investor Contact: Sue Morris (650) 225-6523 Advocacy Contact: Kristin Reed (650) 467-9831 FDA APPROVES AVASTIN IN COMBINATION WITH CHEMOTHERAPY

More information

Reliable. results. efficiently. for CH, galactosemia, CAH and CF screening

Reliable. results. efficiently. for CH, galactosemia, CAH and CF screening GSP Neonatal assays for CH, galactosemia, CAH and CF screening Reliable results efficiently GSP Neonatal kits DELFIA or enzyme-based fluorescence assays GSP is the new, automated neonatal screening system

More information

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE 37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

Evidence Based Commutability: Bias 2 Study. Janice Gill Manager RCPAQAP Chemical Pathology Adelaide SA

Evidence Based Commutability: Bias 2 Study. Janice Gill Manager RCPAQAP Chemical Pathology Adelaide SA Evidence Based Commutability: Bias 2 Study Janice Gill Manager RCPAQAP Chemical Pathology Adelaide SA Australian Bias Studies conducted by Gus Koerbin, ACT Pathology on behalf of AACB Harmonisation Committee

More information

Reliable, cost-effective CT/GC testing For labs with low to medium throughput needs. The BD ProbeTec ET System

Reliable, cost-effective CT/GC testing For labs with low to medium throughput needs. The BD ProbeTec ET System Reliable, cost-effective CT/GC testing For labs with low to medium throughput needs The BD ProbeTec ET System The demand is there. The system is here. Now your lab can run up to 15,000 samples a year reliably

More information

36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018

36th Annual J.P. Morgan Healthcare Conference. Kevin Conroy, Chairman and CEO January 9, 2018 36th Annual J.P. Morgan Healthcare Conference Kevin Conroy, Chairman and CEO January 9, 2018 1 Safe harbor statement This presentation contains forward-looking statements within the meaning of Section

More information

Sysmex Activities in Russia (in the area of clinical testing) For The 4th Japan-Russian Investment Forum

Sysmex Activities in Russia (in the area of clinical testing) For The 4th Japan-Russian Investment Forum Sysmex Activities in Russia (in the area of clinical testing) For The 4th Japan-Russian Investment Forum Kenji Tachibana Executive Vice President International Business Management What is clinical testing?

More information

CLINITEK Novus Automated Urine Chemistry Analyzer

CLINITEK Novus Automated Urine Chemistry Analyzer CLINITEK, Atlas, Novus, Status+, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc. or its affiliates. All other trademarks are properties of their respective owners. Product

More information

Media Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) (908)

Media Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) (908) News Release Media Contacts: Kelley Dougherty Investor Contact: Graeme Bell (215) 652-0059 (908) 423-5185 Janet Skidmore (267) 305-7715 Merck Launches National Advertising Campaign for GARDASIL, Merck's

More information

Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer

Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer Media Release Roche receives FDA clearance for the VENTANA MMR IHC Panel for patients diagnosed with colorectal cancer The VENTANA MMR IHC Panel 1 helps differentiate between sporadic colorectal cancer

More information

Jefferies Healthcare Conference. John Bishop Chairman & CEO June 2, 2014

Jefferies Healthcare Conference. John Bishop Chairman & CEO June 2, 2014 Jefferies Healthcare Conference John Bishop Chairman & CEO June 2, 2014 1 Cepheid Cepheid Worldwide Market Growth by Segment Overall IVD sales are projected to grow at a 5.9% CAGR through 2017. Molecular

More information

JABRA UNVEILS THE KEY TO ITS INDUSTRY LEADERSHIP

JABRA UNVEILS THE KEY TO ITS INDUSTRY LEADERSHIP JABRA UNVEILS THE KEY TO ITS INDUSTRY LEADERSHIP A cooperative culture and knowledge sharing with sister companies in the sound and hearing Group - GN Store Nord, is key to the industrial leadership and,

More information

DIABETES - FACT SHEET

DIABETES - FACT SHEET DIABETES - FACT SHEET What is diabetes? Diabetes mellitus, often shortened to diabetes, is a chronic condition that affects the body's ability to control blood sugar level and use energy from food. In

More information

Media Contacts: Amy Rose Investor Contact: Graeme Bell (908) (908)

Media Contacts: Amy Rose Investor Contact: Graeme Bell (908) (908) News Release FOR IMMEDIATE RELEASE Media Contacts: Amy Rose Investor Contact: Graeme Bell (908) 423-6537 (908) 423-5185 Tracy Ogden (267) 305-0960 FDA Approves Once-Daily JANUVIA, the First and Only DPP-4

More information

ARK Methotrexate Assay Application Ortho Clinical Diagnostics VITROS 5600 Integrated System and VITROS 4600 Chemistry System

ARK Methotrexate Assay Application Ortho Clinical Diagnostics VITROS 5600 Integrated System and VITROS 4600 Chemistry System C ARK Methotrexate Assay Application Ortho Clinical Diagnostics VITROS 5600 Integrated System and VITROS 4600 Chemistry System Reference No. 5026000100 Intended for the Quantitative Determination of Methotrexate

More information

Your contact. Merck and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody

Your contact. Merck and Pfizer to Present Data at ASCO for Avelumab, an Investigational Anti-PD-L1 Antibody Your contact Merck Media: Gangolf Schrimpf +49 6151 72 9591 Investor Relations: +49 6151 72 3321 News Release Pfizer Media: Sally Beatty +1 212 733 6566 Investor Relations: Ryan Crowe +1 212 733 8160 May

More information

Working in Unison. According to business unit that works in unison. Paolo Pucci, and looks to the future.

Working in Unison. According to business unit that works in unison. Paolo Pucci, and looks to the future. Table of Contents The U.S. Source for the driving force November 8, 2007 Dates to Remember We Asked; You Answered! New Vanguard Web Site Helps Employees Understand Investment Options Test Your Integration

More information

Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801)

Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) (801) News Release Media Contact: Ron Rogers Investor Contact: Scott Gleason (801) 584-3065 (801) 584-1143 rrogers@myriad.com sgleason@myriad.com Myriad Receives FDA Approval of BRACAnalysis CDx as Companion

More information

Total Cost of Ownership (TCO): An evidence-based approach to compare laboratory equipment

Total Cost of Ownership (TCO): An evidence-based approach to compare laboratory equipment Total Cost of Ownership (TCO): An evidence-based approach to compare laboratory equipment P.C.G. Gontard 1, L.I. Stankevich 1, B.G. Gorodetsky 1 SUMMARY Clinical laboratories across the globe operate in

More information

Health Science in the NHS:

Health Science in the NHS: Health Science in the NHS: Getting Ready to Apply Genomic Knowledge into the NHS Angela Douglas, Scientific Director 16 th April 2014 Content of Talk What is Genomics the Science What Genomics can do for

More information

N a s d a q : I N S Y

N a s d a q : I N S Y N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations

More information

Media Contact: Amy Rose Media Contact: Shelley Ducker (908) (240) (908)

Media Contact: Amy Rose Media Contact: Shelley Ducker (908) (240) (908) FOR IMMEDIATE RELEASE News Release Merck contacts: QIAGEN contacts: Media Contact: Amy Rose Media Contact: Shelley Ducker (908) 423-6537 (240) 686-7603 Investor Contact: Eva Boratto Investor Contact: Solveigh

More information

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018

ADM to Acquire Neovia and Probiotics International Limited. July 2, 2018 ADM to Acquire Neovia and Probiotics International Limited July 2, 2018 Safe Harbor Statement 2 Some of our comments constitute forward-looking statements that reflect management s current views and estimates

More information

Bayer Launches Phase III Clinical Study of Trasylol in Elective Spinal Fusion Surgery

Bayer Launches Phase III Clinical Study of Trasylol in Elective Spinal Fusion Surgery Investor News Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Launches Phase III Clinical Study of Trasylol in Elective Spinal Fusion Surgery Study Examines Effects of

More information

G. Snodgrass, K. Ackles, A. Blanco and A. Versaggi Ortho Clinical Diagnostics, Rochester, NY 14626

G. Snodgrass, K. Ackles, A. Blanco and A. Versaggi Ortho Clinical Diagnostics, Rochester, NY 14626 Performance of the EKF Diagnostics, Stanbio β-hydroxybutyrate LiquiColor Assay on the VITROS 4600 Chemistry System and the VITROS 5600 Integrated System. G. Snodgrass, K. Ackles, A. Blanco and A. Versaggi

More information

Private sector commitment to an initiative that links health and prosperity for women

Private sector commitment to an initiative that links health and prosperity for women Private sector commitment to an initiative that links health and prosperity for women Jocelyn Ulrich, Senior Director, Global Healthcare Government and Public Affairs July 10 th, 2018 Healthy women, Healthy

More information

Expanding the boundaries of nutrition Luis Cantarell

Expanding the boundaries of nutrition Luis Cantarell Expanding the boundaries of nutrition Luis Cantarell Nestlé Investor Seminar 30 September 2013 Disclaimer This presentation contains forward looking statements which reflect Management s current views

More information

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor

First Phase 3 Results Presented for a PD-1 Immune Checkpoint Inhibitor September 30, 2014 Positive Phase 3 Data for Opdivo (nivolumab) in Advanced Melanoma Patients Previously Treated with Yervoy @ (ipilimumab) Presented at the ESMO 2014 Congress First Phase 3 Results Presented

More information

Oragenics Shareholder Update

Oragenics Shareholder Update January 4, 2017 Oragenics Shareholder Update Advances Drug Development Programs Focused on Conditions with Significant Unmet Medical Needs TAMPA, Fla.--(BUSINESS WIRE)-- Oragenics, Inc. (NYSE MKT:OGEN.BC),

More information

Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS

Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability

More information

Planning Case Study. Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan

Planning Case Study. Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan Planning Case Study Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan On the vanguard of thought. Reimagining The futurecancer of healthcare Care requires nothing less. Planning

More information

Enzymes. Cell Biology. Monday, November 02, 2015 Mrs Wrightson

Enzymes. Cell Biology. Monday, November 02, 2015 Mrs Wrightson Enzymes Cell Biology 1 Enzymes 2 Recap Enzymes are specific: They only act with one substrate. Watch Me Type of Reaction Substrate Enzyme Product Degradation Starch Amylase Maltose Degradation Protein

More information

Merck & Co, Inc. Announced Approval of JANUVIA TM (INN: sitagliptin), a new oral treatment of diabetes, by the US FDA

Merck & Co, Inc. Announced Approval of JANUVIA TM (INN: sitagliptin), a new oral treatment of diabetes, by the US FDA October 23, 2006 Ono Pharmaceutical Co., Ltd., Public Relations Phone: +81-6-6263-5670 Banyu Pharmaceutical Co., Ltd., Public Relations Phone: +81-3-6272-1001 Merck & Co, Inc. Announced Approval of JANUVIA

More information

Mass Spectrometry Made Simple for Clinical Diagnostic Labs

Mass Spectrometry Made Simple for Clinical Diagnostic Labs Mass Spectrometry Made Simple for Clinical Diagnostic Labs The SCIEX Topaz System with FDA-Cleared Topaz Vitamin D 200M Assay Kit Mass Spectrometry Made Simple SCIEX Topaz System for Clinical Diagnostics

More information

(908) (908)

(908) (908) Contact: Robert J. Hugin Brian P. Gill Senior VP and CFO Director, PR/IR Celgene Corporation Celgene Corporation (908) 673-9102 (908) 673-9530 REVLIMID (lenalidomide) SIGNIFICANTLY DELAYS TIME TO DISEASE

More information

Myriad Genetics Corporate Presentation 6/4/13

Myriad Genetics Corporate Presentation 6/4/13 Myriad Genetics Corporate Presentation 6/4/13 Forward Looking Statement Some of the information presented here today may contain projections or other forward-looking statements regarding future events

More information

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan

NEWS RELEASE Media Contact: Megan Pace Investor Contact: Kathee Littrell Patient Inquiries: Ajanta Horan NEWS RELEASE Media Contact: Megan Pace 650-467-7334 Investor Contact: Kathee Littrell 650-225-1034 Patient Inquiries: Ajanta Horan 650-467-1741 GENENTECH RECEIVES COMPLETE RESPONSE LETTER FROM FDA FOR

More information

Abaxis Piccolo xpress TM

Abaxis Piccolo xpress TM Abaxis Piccolo xpress TM A breakthrough in point-of care diagnostics A breakthrough in point of care diagnostics Fast, easy, accurate on-site testing The Piccolo xpress TM is a fully automated system,

More information

Planning Case Study. Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan

Planning Case Study. Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan Planning Case Study Barbara Ann Karmanos Cancer Institute McLaren Health Care Detroit, Michigan On the vanguard of thought. Reimagining The futurecancer of healthcare Care requires nothing less. Planning

More information

HUMAN NUTRITION 08 MAY 2013

HUMAN NUTRITION 08 MAY 2013 HUMAN NUTRITION 08 MAY 2013 Lesson Description In this lesson, we: Study the structure of the human digestive system Look at the processes used in the human digestive system Look at the two different types

More information

#9 - Digestion. Objectives: Prelab Activity. I Digestive System

#9 - Digestion. Objectives: Prelab Activity. I Digestive System #9 - Objectives: Observe and understand the process of emulsification Understand the digestion of fats by pancreatic lipase and the purpose of bile Understand the digestion of protein by pepsin and the

More information

Minnesota's HealthPartners View of the Future of Integrated Care and Role of Laboratory Testing

Minnesota's HealthPartners View of the Future of Integrated Care and Role of Laboratory Testing Minnesota's HealthPartners View of the Future of Integrated Care and Role of Laboratory Testing May 1, 2018 Rick Panning, MBA, MLS(ASCP) CM Senior Administrative Director, Laboratory Services HealthPartners

More information

- Amendment accelerates anticipated PROSPER top-line results by two years -

- Amendment accelerates anticipated PROSPER top-line results by two years - Pfizer Contacts: For Media Dean Mastrojohn (212) 733-6944 dean.mastrojohn@pfizer.com For Investors Ryan Crowe (212) 733-8160 ryan.crowe@pfizer.com Astellas Contact: For Media Tyler Marciniak (847) 736-7145

More information

Supplemental Appendix

Supplemental Appendix Supplemental Appendix Appendix Table 1. Sub-Categorization of Medical Devices Included in Study Sample vel Medical Devices (N = 309) Cardiovascular Cardiac (ventricular) assist devices Cardiac prosthetic

More information

Investigator Qualification Evidence Gathering: Our Approach to Data Collection

Investigator Qualification Evidence Gathering: Our Approach to Data Collection December 13, 2017 Investigator Qualification Evidence Gathering: Our Approach to Data Collection Teri Swezey, PhD, MA. CTTI Assistant Social Scientist. Project Leader, Duke SOM Overview Brief review of:

More information

INVESTOR MEETING ASTRO 2013

INVESTOR MEETING ASTRO 2013 INVESTOR MEETING ASTRO 2013 Webcast will begin 7:15 a.m. EDT SEPTEMBER 24, 2013 2013 VARIAN MEDICAL SYSTEMS. ALL RIGHTS RESERVED. Forward-Looking Statements Except for historical information, this news

More information

Investor Presentation September Cogstate Ltd. All rights reserved.

Investor Presentation September Cogstate Ltd. All rights reserved. Investor Presentation September 2017 2017 Cogstate Ltd. All rights reserved. We believe that brain health is profoundly important to quality of life and should be easier to measure. That s why we so passionately

More information

Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc

Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc 1 Personalized Medicine Disruptive Technology? David Logan Senior Vice President, Commercial Genomic Health Inc Safe Harbor Statement This presentation contains forward-looking statements within the meaning

More information

Critical Care. Building Future Growth with Innovation. Katie M. Szyman Corporate Vice President, Critical Care

Critical Care. Building Future Growth with Innovation. Katie M. Szyman Corporate Vice President, Critical Care Katie M. Szyman Corporate Vice President, Building Future Growth with Innovation Products Benefit Millions of Patients per Year Our new HemoSphere capital platform strengthens our core portfolio We are

More information

Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter)

Inovio Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event

More information

I, Mary M. Langman, Director, Information Issues and Policy, Medical Library Association

I, Mary M. Langman, Director, Information Issues and Policy, Medical Library Association I, Mary M. Langman, Director, Information Issues and Policy, Medical Library Association (MLA), submit this statement on behalf of MLA and the Association of Academic Health Sciences Libraries (AAHSL).

More information

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer

Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Savolitinib Global Phase II Trial Initiated in EGFR Mutant Non-Small Cell Lung Cancer Initiation of expanded Phase II trials in NSCLC triggers US$10 million milestone from AstraZeneca to Chi-Med New study

More information

Center for Food Safety & Applied Nutrition: Update

Center for Food Safety & Applied Nutrition: Update Center for Food Safety & Applied Nutrition: Update Comments by Ted Elkin Deputy Director for Regulatory Affairs FDA/Center for Food Safety and Applied Nutrition AFDO 2017 Annual Meeting June 20, 2017 Foods

More information

For personal use only. Investor Briefing. Bayswater, 1 st December 2016

For personal use only. Investor Briefing. Bayswater, 1 st December 2016 Investor Briefing Bayswater, 1 st December 2016 Introduction Samantha Cheetham Chief Executive Officer To be an innovative leader in the dental industry, developing our people and partnering with dentists

More information

INTERNATIONAL PRODUCT CATALOG

INTERNATIONAL PRODUCT CATALOG INTERNATIONAL PRODUCT CATALOG Quidel is a leading manufacturer of diagnostic healthcare solutions serving to enhance the health and well-being of people around the globe through the development of diagnostic

More information

Community-Based Point-of-Care Testing: From Innovative Care Model to Common Practice

Community-Based Point-of-Care Testing: From Innovative Care Model to Common Practice Community-Based Point-of-Care Testing: From Innovative Care Model to Common Practice Donald G. Klepser, PhD, MBA Associate Professor University of Nebraska Medical Center Brian Bobby Rite Aid Vice President,

More information

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites

More information

Run glycans up to 5x faster than HILIC

Run glycans up to 5x faster than HILIC FAST GLYCAN LABELING AND ANALYSIS TECHNOLOGY Run glycans up to 5x faster than HILIC HI-RES ANALYSIS AND ID IN MINUTES Run Your Glycans in Record Time High-Resolution Glycan Identification and Quantitation

More information

Chemical and Physical Processes of Digestion

Chemical and Physical Processes of Digestion M57_MARI0000_00_SE_EX08.qxd 8/22/11 3:08 PM Page 394 8 E X E R C I S E Chemical and Physical Processes of Digestion Advance Preparation/Comments 1. Suggest to the students that they become familiar with

More information

QMS TACROLIMUS APPLICATION BECKMAN COULTER AU480 /AU680 /AU5800

QMS TACROLIMUS APPLICATION BECKMAN COULTER AU480 /AU680 /AU5800 QMS TACROLIMUS APPLICATION BECKMAN COULTER AU480 /AU680 /AU5800 Beckman Coulter Reagent REF A53727 The QMS Tacrolimus Immunoassay is intended for the quantitative determination of tacrolimus in human whole

More information

Results of Phase II Studies of Sitagliptin (MK-0431 / ONO-5345) Investigational Treatment for Type 2 Diabetes Presented by Merck & Co., Inc.

Results of Phase II Studies of Sitagliptin (MK-0431 / ONO-5345) Investigational Treatment for Type 2 Diabetes Presented by Merck & Co., Inc. Ono Pharmaceutical Co., Ltd., Public Relations Tel: +81-6-6263-5670 June 13, 2005 Banyu Pharmaceutical Co., Ltd., Public Relations Tel: +81-3-5203-8105 Results of Phase II Studies of Sitagliptin (MK-0431

More information

www. isotopeworld.com Advanced Medical Isotope Corporation

www. isotopeworld.com Advanced Medical Isotope Corporation www. isotopeworld.com Advanced Medical Isotope Corporation www. isotopeworld.com James C. Katzaroff Founder, CEO, Chairman December 5, 2016 Safe Harbor Statement This Overview contains forward-looking

More information

Key Trends for Ambulatory Surgery Centers in 2018

Key Trends for Ambulatory Surgery Centers in 2018 Key Trends for Ambulatory Surgery Centers in 2018 Don Phalen Vice President Business Development, Regent Surgical Health Mark Murphy Chief Strategy Officer, St Joseph s Hospital MOVING TOWARDS VALUE-BASED

More information

REAGENTS THE HIGHEST QUALITY RANGE OF ROUTINE AND NOVEL REAGENTS

REAGENTS THE HIGHEST QUALITY RANGE OF ROUTINE AND NOVEL REAGENTS THE HIGHEST QUALITY RANGE OF ROUTINE AND NOVEL REAGENTS Advancing Biochemistry Testing for Laboratories CONTENTS 01 06 43 46 53 55 60 BENEFITS OF RANDOX REAGENTS REAGENTS - RANDOX THIRD PARTY REAGENTS

More information

DIAZYME PRODUCT LIST LIST INNOVATIONS IN CLINICAL DIAGNOSTICS

DIAZYME PRODUCT LIST LIST INNOVATIONS IN CLINICAL DIAGNOSTICS DIAZYME PRODUCT LIST LIST PRODUCT 2 14 INNOVATIONS IN CLINICAL DIAGNOSTICS About Diazyme Diazyme Laboratories is a Division of General Atomics located in Poway, California. Diazyme uses its proprietary

More information

(212) Investors Contact: Ryan Crowe (212)

(212) Investors Contact: Ryan Crowe (212) For immediate release: February 5, 2014 Media Contact: Sally Beatty (212) 733-6566 Investors Contact: Ryan Crowe (212) 733-8160 Pfizer And Merck To Collaborate On Innovative Anti-Cancer Combination Studies

More information

JOSLIN INGENUITY DIGITAL IMPACT INNOVATION BIG DATA CAPACITY TRANSLATIONAL AGILITY COLLABORATION COLLABORATION JENESIS

JOSLIN INGENUITY DIGITAL IMPACT INNOVATION BIG DATA CAPACITY TRANSLATIONAL AGILITY COLLABORATION COLLABORATION JENESIS CONFIDENCE OUTCOMES ALLIANCES CATALYST COLLABORATION AGILITY JOSLIN INGENUITY CAPACITY IMPACT INNOVATION GLOBAL ACCELERATION COLLABORATION JENESIS BIG DATA TRANSLATIONAL DIGITAL Contents 2 Partnering for

More information

Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma

Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma PRESS RELEASE IMMUNOCORE LIMITED Immunocore and MedImmune announce new collaboration to conduct immuno-oncology combination trials in melanoma (Oxford, UK, 16 April 2015) Immunocore Limited, a world-leading

More information

Sanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes

Sanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes PRESS RELEASE Sanofi Announces Results of ORIGIN, the World s Longest and Largest Randomised Clinical Trial in Insulin in Pre- and Early Diabetes Dublin, Ireland (15 June 2012) Sanofi presented results

More information

MINNEAPOLIS September 12, 2012 Medtronic, Inc. (NYSE: MDT) today announced findings

MINNEAPOLIS September 12, 2012 Medtronic, Inc. (NYSE: MDT) today announced findings NEWS RELEASE Contacts: Wendy Dougherty Jeff Warren Public Relations Investor Relations 707-541-3004 763-505-2696 FOR IMMEDIATE RELEASE HEALTH-ECONOMIC ANALYSIS SUGGESTS MEDTRONIC SYMPLICITY RENAL DENERVATION

More information

SAP s Autism at Work Program Provides Meaningful Employment for People on the Autism Spectrum

SAP s Autism at Work Program Provides Meaningful Employment for People on the Autism Spectrum SAP s Autism at Work Program Provides Meaningful Employment for People on the Autism Spectrum sap.com OVERVIEW SAP is a multinational software company whose research and development locations (SAP Labs),

More information

Structured Pathology Reporting of Cancer Newsletter

Structured Pathology Reporting of Cancer Newsletter Structured Pathology Reporting of Cancer Newsletter December 2012. Issue 12. Index : (click on a title below to go directly to that story) Welcome to the last edition of the Structured Pathology Reporting

More information

The process by which nutrient molecules pass through the wall of your digestive system into your blood. ABSORPTION AS RELATED TO DIGESTION

The process by which nutrient molecules pass through the wall of your digestive system into your blood. ABSORPTION AS RELATED TO DIGESTION ABSORPTION AS RELATED TO DIGESTION The process by which nutrient molecules pass through the wall of your digestive system into your blood. 3 FUNCTIONS OF DIGESTION Breaks down food into molecules the body

More information

R&D AND INNOVATION. Francesco Colotta Senior Corporate VP and Chief Medical Officer

R&D AND INNOVATION. Francesco Colotta Senior Corporate VP and Chief Medical Officer R&D AND INNOVATION Francesco Colotta Senior Corporate VP and Chief Medical Officer IN VITRO DIAGNOSTICS: BASICS DETECTION IN BIOLOGICAL FLUIDS... E.G. BLOOD, URINE, CSF, IN VITRO DIAGNOSTICS...OF A MOLECULE......

More information

Elekta R&D Update 22 January 2015, Utrecht

Elekta R&D Update 22 January 2015, Utrecht 1 Elekta R&D Update 22 January 2015, Utrecht Elekta R&D Update - 22 January 2015, Utrecht 11.00 R&D Update Niklas Savander President and CEO 11.15 Atlantic Positioning Dee Mathieson, SVP Oncology Business

More information

ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan

ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan ONO PHARMACEUTICAL CO., LTD. and Bristol-Myers Squibb Announce Strategic Immuno-Oncology Collaboration in Japan, South Korea and Taiwan Companies to develop and commercialize Opdivo (nivolumab), ipilimumab,

More information

Focusing our energy on saving lives

Focusing our energy on saving lives October 2017 The Outlook for Oncology: The Shrinking, Affordable Proton Therapy Center Focusing our energy on saving lives Jonathan Farr, DSc Senior Vice President Medical Physics Forward Looking Statement

More information

Cepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012

Cepheid The MDx Growth Leader. William Blair Growth Stock Conference June 12, 2012 Cepheid The MDx Growth Leader William Blair Growth Stock Conference June 12, 2012 Forward Looking Statement During the course of this presentation, we may make projections or other forward looking statements

More information

Dr. Manfred Eggersdorfer Senior Vice President Research & Development DSM Nutritional Products

Dr. Manfred Eggersdorfer Senior Vice President Research & Development DSM Nutritional Products INTERNATIONAL CONFERENCE ON CSR AND COMBATING MALNUTRITION: OBTAINING MILLENNIUM DEVELOPMENT GOALS (MDGs) IN INDONESIA Keynote Address Dr. Manfred Eggersdorfer Senior Vice President Research & Development

More information

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO

IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics. Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO IMMUNOMEDICS, INC. Advanced Antibody-Based Therapeutics Oncology Autoimmune Diseases Jefferies 2014 Global Healthcare Conference Cynthia L. Sullivan, President and CEO Forward-Looking Statements This presentation,

More information

More cancer patients are being treated with immunotherapy, but

More cancer patients are being treated with immunotherapy, but Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors PRINCETON, N.J. & SOUTH

More information